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Abstract Presenilin 1 (PS1) is a key factor for L-amyloid (Ab)
formation in Alzheimer disease (AD). Homocysteine accumula-
tion, frequently observed in AD patients, may be a sign of a
metabolic alteration in the S-adenosylmethionine (SAM) cycle,
which generates the overexpression of genes controlled by meth-
ylation of their promoters, when the cytosine in CpG moieties
becomes unmethylated. The methylation of a gene involved in
the processing of amyloid precursor protein may prevent Ab
formation by silencing the gene. Here we report that SAM
administration, in human neuroblastoma SK-N-SH cell cultures,
downregulates PS1 gene expression and Ab production.
+ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Many lines of evidence sustain the amyloid theory as the
cause of Alzheimer disease (AD) [1,2]. The perspective of
eliminating directly a portion of the neurotoxic amyloid pep-
tide is certainly appealing. The most relevant attempt,
although unsuccessful, has been anti-amyloid vaccination [3].
Although there are divergent opinions on the outcome of anti-
amyloid vaccine and developments are in progress, the vaccine
experiments have focused on two considerations: the ¢rst is
that the target is probably correct, since vaccinated animals
recovered cognition along with a lowering of free amyloid and
plaques [4] ; the second is that amyloid has important physio-
logical functions [5], and as such cannot be completely elim-
inated [6]. We feel that a molecular intervention resulting in a
restored physiological level of the enzymes involved in amy-
loid precursor protein (APP) processing and the prevention of
L-amyloid peptide (Ab) overproduction would be a better
approach.
A few papers indicated the possible role of increased ho-
mocysteine (HCY) as a risk factor in AD [7] and the de-
creased concentration of S-adenosylmethionine (SAM) mea-
sured post mortem in AD patients [8,9]. One alteration of
SAM metabolism, which can modify gene expression, is the
decreased uptake of folate and vitamin B12 with consequent
HCY and S-adenosylhomocysteine (SAH) accumulation and
SAM reduction [10]. Besides the lack of transformation of
HCY to methionine [11], lower SAM levels could be due to
methionine adenosyltransferase de¢ciency [12]. The lower
availability of SAM could very well be related to the altered
expression of genes involved in APP metabolism, ¢nally pro-
ducing the accumulation of Ab peptide. SAM is the main
methyl donor and could regulate the methylation status of a
gene whose product is involved in APP processing, thus pre-
venting Ab formation by silencing the gene.
K-Secretase cleavage of APP does not produce the amyloid-
ogenic peptides, produced, on the contrary, by L- and Q-sec-
retase activities [13]. Many papers have contributed to the
further explanation of the close connection between presenilin
(PS) 1 and Q-secretase [14^16]. The physiological role of pre-
senilins is demonstrated by the discovery that PS1 de¢ciency
in mice was lethal [17] ; this appears to be strictly connected to
the activation of Notch-1, a signal transductor involved in
stem cell maturation [18]. All the indications regarding PS1
as the target for AD therapy point to the silencing of this
gene, but without a complete blocking [19]. Two observations
have been basic for the development of this work: the gradual
DNA hypomethylation in the elderly [8,9] and the accumula-
tion of HCY in AD patients [7]. These two conditions are
metabolically related, since the lack of transformation of
HCY to methionine reverts the metabolism to SAH, a strong
inhibitor of DNA methyltransferases, inducing DNA hypo-
methylation [20]. This biochemical pattern, according to the
theory that many genes are expressed when the cytosines in
CpG moieties of their promoters become unmethylated
[21,22], could determine either the expression of unexpressed
genes or the overexpression of genes normally expressed. PS1
overexpression could unbalance the processing of the Ab pep-
tide which therefore accumulates and after several years could
cause brain degeneration. We propose that the alteration of
HCY and SAM metabolism could be related to the onset of
AD as schematically represented in Fig. 1. We have already
shown that gene expression may be repressed by remethyla-
tion [23].
2. Materials and methods
2.1. Cell culture
The SK-N-SH human neuroblastoma cell line was cultured in F14
medium with 8% foetal calf serum (growth medium, GM) or with 1%
foetal calf serum and 10 WM retinoic acid (di¡erentiation medium,
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DM); 100 WM SAM was added to DM according to experimental
design. Cultures were re-fed every second day; the times indicated are
referred to medium shift (or change) as day 0. The experiment was
repeated three times, giving similar results.
2.2. HPLC assays
Cell lysis, macromolecules precipitation and high performance liq-
uid chromatography (HPLC) measurements were carried out as pre-
viously described [23].
2.3. Nucleic acid analysis
RNA and DNA extractions were performed by standard proce-
dures [24]. Expression studies by reverse transcription polymerase
chain reaction (RT-PCR) were performed on 1 Wg of total RNA,
using 50 pmol of oligo-d(T)16 and 50 units of M-MuLV reverse tran-
scriptase at 42‡C for 1 h, as indicated by the manufacturer. PCR
assays were carried out as previously described [23]; L-actin was
used as a standard for the subsequent densitometric analysis. For
each gene, we performed several ampli¢cation reactions with di¡erent
numbers of cycles (20^40), choosing the reactions in the linear loga-
rithmic phase for the semi-quantitative analysis [24].
DNA methylation assays were performed by multiplex HpaII PCR
[23,24]. Genomic DNA was treated separately with two restriction
endonucleases: EcoRI, which has no recognition sites internal to the
ampli¢ed gene region, and HpaII, which has recognition sites internal
to the 5P-£anking region and is methylation-sensitive (it fails to cut if
the CCGG recognition sequence is methylated at any C). Intron 2,
which possesses no HpaII or EcoRI recognition sites, was used as the
internal standard. EcoRI-digested samples were ampli¢ed to prove
that the investigated regions could be ampli¢ed in all experimental
conditions, thus demonstrating that the absence of a fragment was
only dependent on HpaII digestion. In each case, 2 Wg of genomic
DNA was digested overnight at 37‡C with 5 units of enzyme, and then
with 3 units more for an additional 6 h, in a ¢nal volume of 40 Wl of
appropriate bu¡er (Roche Diagnostics). PCR reactions were carried
out as described above for the semi-quantitative analysis.
GenBank accession numbers, primers sequence and position, ex-
pected products and annealing temperatures are as follows:
1. L-actin (M10277): L-actF 5P-AAGAGAGGCATCCTCACCCT-3P
(nt 1405^1424, exon 3), L-actR 5P-TACATGGCTGGGGTGTT-
GAA-3P (nt 2044^2063, exon 4); 218 bp, 58‡C;
2. APP (Y00264): HSAPPP11 5P-GCTGGTGGAGACACACATG-
GCC-3P (nt 1278^1299, exon 11), HSAPPM7 5P-GGATCTGA-
GCGGCTTTCTTGGG-3P (nt 1480^1501, exon 12); 224 bp, 58‡C;
3. PS1 (L42110): HSPS1P5 5P-ACGACCCCAGGGTAACTCCCG-
3P (nt 407^427, exon 5), HSPS1M1 5P-CTCTCTGGCCCACA-
GTCTCGG-3P (nt 613^633, exon 6); 227 bp, 58‡C;
4. PS2 (NM_000447): HSPS2P1 5P-GAAAGCCAGGGAGCATCA-
TTCATTTAGCC-3P (nt 257^285, exon 3), HSPS2M1 5P-GAA-
GTTCCAAGACAGTCAGCAAGAGGGTGG-3P (nt 972^1000,
exon 5); 744 bp, 62‡C;
5. PS1 methylation (L76528): HSPS1P7 5P-TATAGGGGCTTT-
CGTCCTCAGCTCG-3P (nt 481^505), HSPS1M11 5P-AGGTTC-
CTTCCAGACCAGCCG-3P (nt 771^791), 5P-£anking, 312 bp;
HSPS1P6 5P-GAAGTCCGCACGCCTCTTGTTCG-3P (nt 1256^
1278), HSPS1M12 5P-TCACCTCAATTCTCTCACCCATCCC-3P
(nt 1435^1459); internal standard, intron 2, 204 bp, 64‡C.
2.4. Gel electrophoresis and analysis of PCR products
PCR products were examined by electrophoresis in 1.2% agarose
gels. Each gel was acquired and analysed on a computerised densi-
tometer (Fluor-S MultiImager, Bio-Rad). Fragment speci¢city was
assessed by restriction analysis.
2.5. Western blot analysis
Cells were lysed with 50 mM Tris^HCl pH 7.4, 150 mM NaCl, 0.2%
Nonidet P-40, 1% CHAPS, 2 mM EDTA, phenylmethylsulfonyl £uo-
ride (200 WM), leupeptin (1 WM), pepstatin A (1 WM), calpain inhib-
itor I (5 WM), all from Sigma. 20 Wg of each protein extract was run
on 6% (APP) or 12% (PS1 and PS2) sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis, then blotted onto nitrocellulose.
APP was detected by monoclonal antibody NCL-APP (Novocastra)
recognising particularly the 110 kDa band. PS1 was detected by
monoclonal antibody MAB 5232 (Chemicon) recognising a 18^20
kDa band. PS2 was detected by goat polyclonal antibody sc-1456
(Santa Cruz) recognising a 100 kDa band. 14-3-3L was detected by
rabbit polyclonal antibody sc-629 (Santa Cruz) recognising a 30 kDa
band.
2.6. ELISA test
Media were collected and concentrated using centrifugal ¢lter de-
vices (Centricon YM-3, Amicon). Ab(1^40) was analysed with Immu-
noassay Kit (BioSource International). All measurements were per-
formed in duplicate.
3. Results and discussion
3.1. Rationale
The rationale of this study was to investigate which genes,
involved in amyloid production, were regulated by methyla-
tion. Experiments were designed to show the regulation of
gene expression, their methylation and protein synthesis after
treatment with SAM. HPLC experiments in cell lysates from
Fig. 1. Schematic representation of the relation between DNA demethylation and Ab production. a: Promoter demethylation causes the upreg-
ulation of PS1 expression and Q-secretase activity, with a consequent increase in L-amyloid production. b: DNA methylation can be reduced by
ageing or nutritional de¢ciencies and is at least partially avoided or restored by SAM administration.
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SAM-treated cultures showed a SAM uptake six times higher
than controls (data not shown).
3.2. Regulation of gene expression
Gene expression was studied by RT-PCR as shown in Fig.
2 (typical RT-PCR assays as obtained from di¡erent cell ex-
periments and ampli¢cations). The right-hand panels show the
semi-quantitative densitometric analysis of RNA expression;
histogram bars are expressed as percentageR S.E.M., with the
highest value taken as 100%. APP, PS1 and PS2 showed a
peak of expression at 96 h, both in GM and in DM. The
expression pattern of these genes seemed to be independent
of cell di¡erentiation; only APP was slightly upregulated in
DM. Presence of 100 WM SAM (lanes 6 and 7) did not alter
the expression pattern of APP and PS2: the expression level
was higher at 96 h. PS1 expression, in contrast (panel b, lane
7), was markedly downregulated (over 50%) at 96 h.
3.3. DNA methylation
APP and PS1 promoters have several CpG sites; we studied
two of them in APP and four in PS1, with HpaII/PCR. The
two CCGG sites in the APP promoter (nt 3328^3331 and
3499^3502; accession number X12751) were found to be al-
ways unmethylated and three sites in the PS1 promoter (nt
612^615, 681^684 and 735^738) always methylated (data not
shown). Only one site in the PS1 promoter (nt 451^454) was
unmethylated or methylated according to the expression level
of the gene, as evident in Fig. 3. Electrophoresis of the HpaII/
PCR products clearly shows that SAM greatly reduced de-
methylation normally occurring in DM after 72 h (lanes 12
and 14). The graph (b) shows the optical densities of 5P-£ank-
ing versus internal standard PCR products (HpaII-digested
samples) ; histograms bars are expressed as percentage R
S.E.M., with the highest value taken as 100%. This experiment
reinforces the observation that SAM could inhibit RNA ex-
pression of PS1 by the methylation of its gene promoter.
3.4. Protein synthesis
In Fig. 4 are shown APP (a), PS1 (b) and PS2 (c) Western
Blots of SK-N-SH cell extracts; the right-hand panels (d^f)
show the optical density values normalised versus the optical
densities of 14-3-3L signals (a^c, lower panels). Histogram
bars are expressed as percentageR S.E.M., with the highest
value taken as 100%. The 110 kDa APP isoform increased
in DM and was only slightly reduced by SAM (panels a
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Fig. 2. SAM modulates presenilin RNA expression. Expression of
APP (a), PS1 (b) and PS2 (c) after 48 and 96 h in GM (lanes 2,3),
DM (lanes 4,5) and in DM in the presence of 100 WM SAM (lanes
6,7). d^f: Densitometric quanti¢cation of experiments as in a^c, re-
spectively, obtained by optical density (O.D.) of PCR fragments
normalised with O.D. of L-actin (not shown) (b: blank; MM: mo-
lecular weight marker).
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Fig. 3. SAM inhibits PS1 promoter demethylation. a: EcoRI panel,
to the left, as positive control, and HpaII panel, to the right, as
methylation-sensitive experiments in GM (lanes 2,3 and 9,10), DM
(lanes 4,5 and 11,12) and DM in the presence of 100 WM SAM
(lanes 6,7 and 13,14). b: Densitometric quanti¢cation of O.D. of 5P-
£anking PCR fragments normalised with O.D. of internal standard.
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Fig. 4. SAM modulates protein synthesis in SK-N-SH. Protein levels
of APP (a), PS1 (b) and PS2 (c) after 96 and 144 h in GM (lanes
1,2), DM (lanes 3,4) and in DM in the presence of 100 WM SAM
(lanes 5,6). d^f: Densitometric quanti¢cation of experiments as in
panels a^c (O.D. of protein bands normalised with O.D. of 14-3-3L
bands).
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and d). PS1 protein, in contrast, was synthesised at similar
levels in GM and DM but was markedly reduced by SAM
(panels b, lanes 5 and 6), in agreement with the results dis-
played in gene expression. PS2 protein synthesis seemed to be
unmodi¢ed (panels c and f).
To con¢rm the e⁄cacy of SAM treatment on L-amyloid
processing, we wanted to demonstrate that PS1 promoter
methylation, RNA downregulation and protein synthesis in-
hibition observed in the presence of SAM also resulted in a
lowered secretion of Ab peptide. The ¢nal result of reducing
L-amyloid production by six-fold is shown in Fig. 5.
3.5. Conclusions
The data presented in this paper suggest the possibility of
therapeutically reducing Ab production. It is unclear whether
Ab accumulation is due to its overproduction or to a clear-
ance defect. However, the reduction of Ab formation has a
good chance of preventing AD. We are convinced that the
balance of presenilin activity or of their expression could be
primarily responsible for Ab accumulation. The progressive
SAM reduction observed in the elderly and the consequent
methylation decrease, on the one hand, and our data showing
that the PS1 gene is regulated by methylation, on the other,
seem to substantiate our theory.
In HpaII/PCR experiments on PS1 promoters, we showed
that SAM downregulates PS1 expression, remethylating at
least one CpG site. Under these conditions, Ab production
was reduced about six-fold. PS1 is involved in Notch-1 cleav-
age [25], in neuronal di¡erentiation [26] and probably in other
physiological functions. We veri¢ed that SAM did not inter-
fere with Notch-1 expression (data not shown). We cannot
control correct Notch-1 processing, since protein levels in
non-transfected cells are too low to be measured.
SAM acts in a physiological manner, partially silencing
PS1, being a natural product and a basic body metabolite.
We would like to stress that Ab accumulation in the central
nervous system is a physiological change in ageing, excessive
in AD, that should be lowered to levels not interfering with
cognitive functions. The downregulation of PS1 expression by
SAM is a mild intervention since a basal level of gene expres-
sion is maintained; this is in agreement with the slow Ab
accumulation process in AD, due to minor changes in PS1
activity. This is a major point in favour of our method com-
pared to the hypothesis of completely blocking PS1 activity.
The modulation of gene methylation processes could be the
target for preventing AD or controlling the progression of the
disease. The simplest explanation for HCY accumulation and
SAM reduction in AD patients could be the reduction of B12,
B6 and folic acid levels [27,28], since these vitamins are essen-
tial for the transformation of HCY to methionine. SAM re-
duction could be one of the main factors producing the typical
metabolism modi¢cations in ageing, indeed it is an emerging
idea that other pathologies are associated with hyperhomo-
cysteinaemia (e.g. vascular diseases).
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Fig. 5. Inhibition of L-amyloid(1^40) production. ELISA test per-
formed on media collected from SK-N-SH cell cultures; *P6 0.05
compared to DM, n=4 (ANOVA test).
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